enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Down 90.4% in August

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totaling 4,663 shares, a drop of 90.4% from the August 15th total of 48,573 shares. Based on an average daily trading volume, of 13,212 shares, the days-to-cover ratio is currently 0.4 days.

More enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Reported short interest fell sharply to 4,663 shares as of August 31, down 90.4% from the prior reporting period. A later update reported zero shares sold short as of September 10, which could reduce bearish trading pressure. However, the conflicting figures and very small share counts suggest the data may have limited predictive value.
• Neutral Sentiment: The supplied articles about Toyota diesel engines, submerged engines, vehicle recalls, Ford’s use of artificial intelligence, Ford Edge investigations, diesel reliability, GE Aerospace, and naturally aspirated engines are unrelated to enGene’s business and are unlikely to affect ENGNW directly.
• Negative Sentiment: With no new favorable corporate catalyst identified and average trading volume remaining low, ENGNW may continue to be highly volatile and susceptible to liquidity-driven price movements. The stock’s position well below its 200-day moving average also indicates continued long-term weakness.

enGene Stock Performance

Shares of NASDAQ ENGNW traded down $0.00 during trading hours on Friday, reaching $0.23. 1,814 shares of the stock traded hands, compared to its average volume of 16,250. enGene has a 52-week low of $0.11 and a 52-week high of $4.20. The company’s 50-day simple moving average is $0.29 and its two-hundred day simple moving average is $1.07.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.